Hester Biosciences Q2 FY27: consolidated PAT +44% YoY as EBITDA margin expands to 37%
PAT +44% YoY · revenue +38% · margins expanding
₹97.91 Cr
+38% YoY
₹20.63 Cr
+44% YoY
20.75%
+3pp YoY
₹23.94
Hester Biosciences' consolidated (primary) revenue came in at ₹97.91 Cr, up 38% YoY and 27% QoQ, with PAT of ₹20.63 Cr, up 44% YoY as reported (~41% on an adjusted basis stripping a minor ₹0.42 Cr exceptional gain this quarter — the year-ago quarter had no exceptional items, so the YoY comparison is largely clean). Standalone, the core India entity, posted revenue of ₹82.93 Cr (+28% YoY) and PAT of ₹16.66 Cr (+131% YoY). This is a micro-cap with no analyst consensus coverage located for this print, so street expectations are unknown rather than beaten or missed.
Q2 FY-2027 vs prior quarters
The growth was margin-led as much as volume-led: standalone gross margin rose to 78% from 68% a year ago and EBITDA margin to 35% from 21%, which management attributes to a favourable product mix and cost discipline; consolidated EBITDA margin expanded to 37% from 33%. Poultry Healthcare (standalone) grew revenue 27% YoY on institutional penetration and customer engagement, while Animal Healthcare grew 34% YoY in the quarter on tender execution — though H1 Animal Healthcare revenue is still down 14% YoY on a weak Q1 tender cycle, a seasonality/timing effect rather than demand loss. Management's own framing credits consolidated growth primarily to "the strong performance of the India business," with international operations "broadly stable."
The stock went into the print at ₹2,479.1, up 13.5% over the past month of trading.
For context: this is the second-highest quarterly PAT of the last 6 quarters.
No formal forward guidance. Management maintains long-term confidence in biologicals portfolio, international expansion, and R&D pipeline (Brucella recombinant, LPAI vaccine commercialization) but refuses specific FY27 revenue/margin targets. Africa tax-free status till 2030.
Management gave no formal FY27 revenue or margin guidance at the last concall and none accompanies this result either; that stance is unchanged. The headline QoQ swing — consolidated PAT down 79% from ₹96.73 Cr in Q1 FY27 — is not a deterioration: Q1's figure was inflated by an ₹85.77 Cr non-recurring gain after Hester Africa's loan with the Gates Foundation was amended (principal cut from USD 12 Mn to USD 5 Mn, accrued interest waived, remaining balance made interest-free), booked as an Ind AS 109 extinguishment gain. Stripped of that, Q2's underlying consolidated performance is a sequential improvement, not a decline. Alongside results, the board approved a fresh unsecured USD 1 Mn loan to Hester Africa (9% interest, 3-year tenure) and the company completed divestment of its remaining 11% stake in Texas Lifescience Pvt Ltd, concluding the partial exit begun with last year's 43.81% stake sale.
W1
Whether consolidated EBITDA margin holds near 37% (vs 33% a year ago) once the one-off's residual effects fully roll off in Q3
W2
Animal Healthcare division: Q2 grew 34% YoY on tender execution but H1 is still -14% YoY — watch if Q3 tender flow sustains the recovery
W3
Utilisation of the new USD 1 Mn Hester Africa loan (agreement expected by 15 November 2026) against stated international expansion plans
Consolidated PBT (₹26.454 Cr) = totalIncome−totalExpenses (₹24.131 Cr) + JV profit share (₹1.904 Cr) + exceptional gain (₹0.419 Cr) — both sit below the 'total expenses' line by design. Year-ago quarter had no exceptional item, so YoY is clean; QoQ is distorted by Q1 FY27's ₹85.77 Cr one-time Gates Foundation loan-modification gain at Hester Africa.
Informational and educational content only. Not investment advice.